Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Panvalent Prophylactic Hepatitis C Virus Vaccine

EF 2014-15

Résumé
Novel direct acting antivirals hold promise for individuals chronically infected with Hepatitis C Virus. However, the high cost of these therapeutics will limit their use in both developing and developed economies. Ultimately, to reduce the global disease burden of Hepatitis C, a cheap, prophylactic, and universal vaccine must be developed. Recent insights provide renewed hope of this possibility, as the factors involved in natural clearance become increasingly elucidated. The importance of both cellular and humoral responses in natural clearance are established, but generating inoculum capable of inducing the requisite state of immunological protection has been elusive. Crucially, HCV is vulnerable to neutralization by antibody, and robust HCV-specific AB response is correlated with clearance and protection from infection. Unfortunately, the induction of HCV-AB has not been a tenable vaccine end point, as the extreme variability of the virus prevents vaccine induced AB from affording universal protection in a real world setting. To overcome this barrier, our team proposes a novel method of vaccine development that harvests the current, circulating viral variability from clinical isolates. We hypothesize that such an inoculum will be capable of generating antibody to the full spectrum of HCV variance. If successful, this novel approach, termed panvalent vaccination, could become a cornerstone to the development of vaccines for all highly variable viruses.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
331487
Name
Mosa Alexander I
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Panvalent Prophylactic Hepatitis C Virus Vaccine
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Glycoprotein; Hepatitis C Virus; Novel; Prevention; Vaccine; Variable
Abstract
Novel direct acting antivirals hold promise for individuals chronically infected with Hepatitis C Virus. However, the high cost of these therapeutics will limit their use in both developing and developed economies. Ultimately, to reduce the global disease burden of Hepatitis C, a cheap, prophylactic, and universal vaccine must be developed. Recent insights provide renewed hope of this possibility, as the factors involved in natural clearance become increasingly elucidated. The importance of both cellular and humoral responses in natural clearance are established, but generating inoculum capable of inducing the requisite state of immunological protection has been elusive. Crucially, HCV is vulnerable to neutralization by antibody, and robust HCV-specific AB response is correlated with clearance and protection from infection. Unfortunately, the induction of HCV-AB has not been a tenable vaccine end point, as the extreme variability of the virus prevents vaccine induced AB from affording universal protection in a real world setting. To overcome this barrier, our team proposes a novel method of vaccine development that harvests the current, circulating viral variability from clinical isolates. We hypothesize that such an inoculum will be capable of generating antibody to the full spectrum of HCV variance. If successful, this novel approach, termed panvalent vaccination, could become a cornerstone to the development of vaccines for all highly variable viruses.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mosa, Alexander I
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~